Navigation Links
Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
Date:4/18/2011

and has been instrumental in its growth during his six and a half years at the Company," said Mr. Crowley. "He has a strong track record of success throughout his 18-year career in the field of rare disease drug development, having overseen the advancement of novel therapies through development into commercialization. I am confident Matt has the experience and capabilities to lead Amicus during this important time in the Company's history."

Mr. Patterson joined Amicus in December 2004 as Chief Business Officer and became Chief Operating Officer in September 2006. He was recently appointed President in February 2011 in recognition of his significant contributions to the Company's success. Prior to Amicus, Mr. Patterson served in positions of increasing responsibility at biopharmaceutical companies focused on rare disease drug research, development, and commercialization, including BioMarin Pharmaceutical Inc. and Genzyme Corporation.

Mr. Crowley will serve as Executive Chairman and a member of the Board of Directors until October 2011, with a possible extension for up to three months upon the mutual agreement of Mr. Crowley and the Company.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare diseases.  The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program is in Phase 3 for the treatment of Fabry disease. 

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
2. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
3. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
4. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
5. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
6. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
7. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
8. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
9. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
10. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
11. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 Remedy Informatics, ... healthcare and life sciences research, today announced it ... (GSA) IT Schedule 70 supply contract (GS-35F-367AA, effective ... provide innovative IT solutions to government agencies at ... this contract, Remedy has placed its products and ...
(Date:6/18/2013)... June 18, 2013  Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a general corporate update in conjunction with ... Tuesday, June 25 at 2:10 p.m. Pacific Time in ... the meeting is as follows: 2:00 p.m. – 2:10 p.m. ... of April 26, 2013) 2:10 p.m. – 3:15 p.m. Corporate ...
(Date:6/17/2013)... , June 17, 2013  Hanger, Inc. (NYSE:  HGR) ... agreement that increases its senior secured facilities to an ... previously.  The new credit agreement includes a $200 million ... facility.  The previous credit agreement was comprised of a ... term loan.  Each new facility matures on June 17, ...
Breaking Medicine Technology:Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 3
... Matrox Graphics Inc., the leading manufacturer of specialized graphics ... the Matrox Xenia(TM) display controller boards ... workstations . The software suite contains a number ... including Radiology Information System (RIS), Picture Archiving and Communication ...
... FOREST, Ill., Oct. 29 Today Hospira, Inc. (NYSE: ... analgesia (PCA) infusion system. Introduced in 1984, Hospira,s PCA was ... was a simple concept: patients know best when they are ... medication. Over the past 25 years, PCA technology has improved ...
Cached Medicine Technology:Rogan-Delft Approves Matrox Xenia Series for Use With Zillion Suite 2Rogan-Delft Approves Matrox Xenia Series for Use With Zillion Suite 3Healthcare Industry Celebrates 25 Years of Advanced Pain Management With PCA Infusion System 2Healthcare Industry Celebrates 25 Years of Advanced Pain Management With PCA Infusion System 3Healthcare Industry Celebrates 25 Years of Advanced Pain Management With PCA Infusion System 4
(Date:6/18/2013)... TX (PRWEB) June 18, 2013 ... launched his new website, thebestbreast.com, showcasing his unique ... women with information about his surgical method and ... , Outlined on his website, Dr. Tebbetts compares ... the traditional methods, Dr. Tebbetts’ method does not ...
(Date:6/18/2013)... have discovered and mapped the signaling network between two ... could cut off cancer cell growth at its starting ... University of Texas MD Anderson Cancer Center reported the ... cancer drug target, and MCM7, a protein vital to ... issue of Cancer Cell . , "MCM7 overexpression ...
(Date:6/18/2013)... 18, 2013 myCNAjobs announces the addition ... downloads, articles, and tips to the Caregiver Resources Center. ... for the 10,000+ retiring baby boomers each day, the ... caregiver job resources has never been greater. ... community, recently launched the first-ever free resource center ...
(Date:6/18/2013)... City, UT (PRWEB) June 18, 2013 ... on Health Reimbursement Accounts . Zane Benefits, which ... health benefits, is the leader in defined contribution ... According to Zane Benefits’ website, employees of a company ... (HRA) may have questions about how Health Reimbursement Accounts ...
(Date:6/18/2013)... By studying one of the most successful Facebook ... successful strategies in his article What We Can Learn ... , The inspirational brand Gollan refers to is the ... impressive 62 million followers (and rising). , The brand ... Pages earlier this year. The Facebook data tracking publication ranked ...
Breaking Medicine News(10 mins):Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:myCNAjobs Adds New Resources to Growing Caregiver Career Center 2Health News:Zane Benefits Publishes New Information on Health Reimbursement Accounts 2Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 2Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 3
... 2008 -- In the December issue of ... Nickel and associates report on the evidence of ... tract symptoms (LUTS) in men enrolled in the ... of prostate Cancer Events) trial is a 4-year, ...
... Northridge Hospital Medical,Center (Northridge) credits TeleHealth Services, ... the organization,s recent awards and top,accreditation, all ... comfort as its medical experts provide superior ... acute care facility located in Northridge, CA,Northridge ...
... Indication for Bothersome Vaginal Symptom Associated,With Menopause, ... Cream 0.5 g has been approved by the ... indication and a new less,frequent twice-weekly dosing regimen ... intercourse) announced Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: ...
... traditional chemotherapy agents with targeted therapies called monoclonal ... in patients with advanced non-small cell lung cancer ... Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ... The combination of bevacizumab and chemotherapy has been ...
... A new research study underway at Cardiff University ... treatment failure among patients with end-stage kidney disease. ... Inflammation Interdisciplinary Research Group at the School of ... the ,Renal Discoveries - The Baxter Extramural Grant, ...
... one of those shoppers who,wake up at 4am on Black ... "It is important not to disturb your circadian rhythm ... SSA. "The body,operates better on a good night,s sleep which ... of dawn the day after Thanksgiving.", SSA retailers nationwide ...
Cached Medicine News:Health News:Relationship between prostate information and lower urinary-tract symptoms evident 2Health News:TeleHealth Services' TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center 2Health News:TeleHealth Services' TIGR(R) Interactive Patient Education System Facilitates Award-Winning Results at Northridge Hospital Medical Center 3Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 2Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 3Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 4Health News:Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients 2Health News:Cardiff scientists study acute infection in end-stage kidney disease patients 2Health News:Don't Disturb Your Circadian Rhythm This Black Friday 'Sleep In, Nap Later,' says Specialty Sleep Association 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: